Differentiated megakaryocyte line producing novel megakaryocyte differentiation factor
AssigneeNew England Deaconess Hospital Corporation
InventorsHava Avraham, Sally Cowley, Jerome Groopman
Life of this patent
Estimating the term…
Abstract
Differentiated megakaryocytes produced by introducing an activated oncogene into blast-megakaryocytes is disclosed. Also disclosed are novel megakaryocyte differentiation factors and platelets obtained from the differentiated megakaryocytes.
Claims6
An isolated extracellular megakaryocyte differentiation factor which mediates differentiation in megakaryocytic cells not transfected with an activated oncogene, wherein said factor has the following characteristics:
- a) is produced and secreted by a differentiated human megakaryocytic cell transfected with an activated ras gene;
- b) is soluble, heat-sensitive and protcase sensitive;
- c) has no detectable GM-CSF, IL-3, IL-1B, or IL-6 activity;
- and
- d) induces an increase in ploidy number in megakaryocytes cultured in the presence of said factor.
An isolated megakaryocyte differentiation factor produced and secreted by the megakaryocytic cell line ATCC No. CRL 10817.
The megakaryocytic cell line ATCC No. CRL 10817.
An isolated megakaryocyte differentiation factor which mediates differentiation in megakaryocytic cells not transfected with an activated oncogene, wherein said factor has the following characteristics:
- a) is present in supernatant obtained from a differentiated human megakaryocytic cell transfected with an activated ras gene;
- b) is soluble, heat-sensitive and protease-sensitive;
- and
- c) has no detectable GM-CSF, IL-3, IL-1B, or IL-6 activity;
- and
- d) induces an increase in ploidy number in megakaryocytes cultured in the presence of said factor.
Dependencies are inferred from the claim text.